A total of eight patients have been enrolled for the clinical trial of the device in the US. Credit: amab / Shutterstock.

Signati Medical has completed enrolment in its first-in-human clinical trial for the sealed vasectomy procedure using the Separo Vessel Sealing System.

The Signati Separo device has been designed to streamline this procedure.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

The investigational device exemption (IDE) trial commenced in April 2024 upon receiving approval from the US Food and Drug Administration (FDA).

A total of eight patients have been enrolled for the trial in the US.

The objective of the trial is to assess the safety and efficacy of the Signati Separo system for vasectomy.

Signati Medical will evaluate the ability of the Separo system to perform vasectomies with lesser procedure times and reduced invasiveness against traditional methods.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The trial’s primary objectives focused on the assessment of post-treatment effectiveness, procedural safety, and semen analysis after the procedure.

Dr Matthew Mutter from LSU Medical Center is the principal investigator of the study.

Mutter said: “The Separo system has the potential to improve the vasectomy experience for both patients and physicians significantly.

“To date, I have been impressed with the device’s ease of use, and we expect final results to be available by the end of the year.”

Signati Medical expects to submit the complete data package to the FDA for obtaining approval this year.

Signati Medical CEO William Prentice said: “We are pleased to announce the completion of enrollment for this groundbreaking clinical trial.

“The participation of all eight patients is a testament to the growing interest in faster and potentially less-burdensome vasectomy options.”